WCM Investment Management LLC Has $3.06 Million Holdings in Pfizer Inc. (NYSE:PFE)

WCM Investment Management LLC grew its position in Pfizer Inc. (NYSE:PFE) by 128.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 115,913 shares of the biopharmaceutical company’s stock after buying an additional 65,238 shares during the quarter. WCM Investment Management LLC’s holdings in Pfizer were worth $3,062,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Retirement Wealth Solutions LLC acquired a new stake in Pfizer during the 4th quarter valued at $26,000. Gladius Capital Management LP grew its holdings in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares in the last quarter. Teachers Insurance & Annuity Association of America acquired a new position in Pfizer during the third quarter valued at $35,000. Joseph Group Capital Management lifted its stake in Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 771 shares in the last quarter. Finally, Sugar Maple Asset Management LLC acquired a new stake in Pfizer during the 4th quarter worth about $43,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PFE has been the subject of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Citigroup decreased their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Wolfe Research assumed coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Finally, StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Down 0.3 %

Shares of Pfizer stock opened at $25.76 on Monday. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a 50 day moving average price of $26.28 and a two-hundred day moving average price of $27.73. The stock has a market capitalization of $145.96 billion, a P/E ratio of 18.27, a PEG ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the business posted $0.10 EPS. Pfizer’s revenue was up 24.7% compared to the same quarter last year. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.68%. Pfizer’s dividend payout ratio is presently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.